[Skip to Content]
[Skip to Content Landing]
June 3, 1998

The Case for Rapid HIV Testing During Labor

Author Affiliations

From the Department of Obstetrics and Gynecology, Maimonides Medical Center, Brooklyn, NY (Dr Minkoff); State University of New York Health Science Center at Brooklyn (Dr Minkoff); and Jackson Memorial Hospital, University of Miami, Miami, Fla (Dr O'Sullivan).

JAMA. 1998;279(21):1743-1744. doi:10.1001/jama.279.21.1743

ZIDOVUDINE administration during pregnancy and the neonatal period reduces the rate of mother-to-child transmission of human immunodeficiency virus (HIV) type 1 by approximately two thirds. Analysis of data from the AIDS Clinical Trial Group (ACTG) 076 cohort1,2 and subsequent reports36 has revealed perinatal transmission rates in the 5% to 8% range in zidovudine-treated groups compared with previously reported rates of 20% or greater in untreated groups.79 In late 1994, the Public Health Service developed recommendations for the use of zidovudine during the antepartum, intrapartum, and neonatal period,10 establishing the national standard of care for identified HIV-infected pregnant women.